pLV312.3 Citations (3)
Originally described in: Treatment of a metabolic liver disease by in vivo genome base editing in adult mice.Villiger L, Grisch-Chan HM, Lindsay H, Ringnalda F, Pogliano CB, Allegri G, Fingerhut R, Haberle J, Matos J, Robinson MD, Thony B, Schwank G Nat Med. 2018 Oct;24(10):1519-1525. doi: 10.1038/s41591-018-0209-1. Epub 2018 Oct 8. PubMed Journal
Articles Citing pLV312.3
| Articles |
|---|
| In vivo adenine base editing of PCSK9 in macaques reduces LDL cholesterol levels. Rothgangl T, Dennis MK, Lin PJC, Oka R, Witzigmann D, Villiger L, Qi W, Hruzova M, Kissling L, Lenggenhager D, Borrelli C, Egli S, Frey N, Bakker N, Walker JA 2nd, Kadina AP, Victorov DV, Pacesa M, Kreutzer S, Kontarakis Z, Moor A, Jinek M, Weissman D, Stoffel M, van Boxtel R, Holden K, Pardi N, Thony B, Haberle J, Tam YK, Semple SC, Schwank G. Nat Biotechnol. 2021 Aug;39(8):949-957. doi: 10.1038/s41587-021-00933-4. Epub 2021 May 19. PubMed |
Cytosine base editing systems with minimized off-target effect and molecular size.
Li A, Mitsunobu H, Yoshioka S, Suzuki T, Kondo A, Nishida K.
Nat Commun. 2022 Aug 8;13(1):4531. doi: 10.1038/s41467-022-32157-8.
PubMed
Associated Plasmids |
Predicting prime editing efficiency and product purity by deep learning.
Mathis N, Allam A, Kissling L, Marquart KF, Schmidheini L, Solari C, Balazs Z, Krauthammer M, Schwank G.
Nat Biotechnol. 2023 Jan 16. doi: 10.1038/s41587-022-01613-7.
PubMed
Associated Plasmids |
If you have published an article using this material, please email us at [email protected] to have your article added to this page.